Delayed
Australian S.E.
12:38:05 2024-05-07 am EDT
|
5-day change
|
1st Jan Change
|
0.66
AUD
|
+1.54%
|
|
+6.45%
|
+15.79%
|
Fiscal Period: Giugno |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
167.1
|
635.2
|
468.6
|
387.4
|
256.9
|
430.8
|
-
|
-
|
Enterprise Value (EV)
1 |
145.6
|
573.5
|
306.7
|
322.7
|
119.9
|
584.5
|
642.6
|
333.6
|
P/E ratio
|
-4.66
x
|
-23.3
x
|
-6.88
x
|
-2.87
x
|
-1.11
x
|
-1.42
x
|
-2.02
x
|
-5.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
183
x
|
786
x
|
4,981
x
|
1,343
x
|
433
x
|
470
x
|
24.7
x
|
2.71
x
|
EV / Revenue
|
159
x
|
709
x
|
3,260
x
|
1,119
x
|
202
x
|
638
x
|
36.8
x
|
2.1
x
|
EV / EBITDA
|
-4.1
x
|
-23
x
|
-4.46
x
|
-2.31
x
|
-0.52
x
|
-2.37
x
|
-3.29
x
|
42.1
x
|
EV / FCF
|
-6.01
x
|
-65.2
x
|
-4.9
x
|
-3.12
x
|
-0.65
x
|
-2.28
x
|
-3.06
x
|
2.99
x
|
FCF Yield
|
-16.6%
|
-1.53%
|
-20.4%
|
-32%
|
-155%
|
-43.8%
|
-32.7%
|
33.4%
|
Price to Book
|
3.36
x
|
6.15
x
|
2.53
x
|
-
|
-27.1
x
|
-2.66
x
|
-2.64
x
|
5.28
x
|
Nbr of stocks (in thousands)
|
249,415
|
269,158
|
351,004
|
352,153
|
467,159
|
662,809
|
-
|
-
|
Reference price
2 |
0.6700
|
2.360
|
1.335
|
1.100
|
0.5500
|
0.6500
|
0.6500
|
0.6500
|
Announcement Date
|
8/8/19
|
8/27/20
|
8/29/21
|
8/29/22
|
8/30/23
|
-
|
-
|
-
|
Fiscal Period: Giugno |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.9148
|
0.8084
|
0.0941
|
0.2884
|
0.5932
|
0.9162
|
17.45
|
159
|
EBITDA
1 |
-35.51
|
-24.92
|
-68.79
|
-139.8
|
-230.9
|
-247
|
-195.1
|
7.929
|
EBIT
1 |
-35.55
|
-25.06
|
-68.94
|
-139.9
|
-231
|
-267.2
|
-222.2
|
-50.1
|
Operating Margin
|
-3,885.6%
|
-3,100.21%
|
-73,284.21%
|
-48,510.06%
|
-38,939.69%
|
-29,170.83%
|
-1,273.78%
|
-31.51%
|
Earnings before Tax (EBT)
1 |
-35.55
|
-25.06
|
-68.94
|
-143.6
|
-228.6
|
-291.7
|
-253.2
|
-103
|
Net income
1 |
-20.91
|
-16.53
|
-62.17
|
-134.5
|
-219.5
|
-277.6
|
-224.5
|
-47.21
|
Net margin
|
-2,285.65%
|
-2,044.67%
|
-66,086.21%
|
-46,640.39%
|
-36,991.82%
|
-30,301.57%
|
-1,286.63%
|
-29.7%
|
EPS
2 |
-0.1437
|
-0.1014
|
-0.1940
|
-0.3826
|
-0.4958
|
-0.4578
|
-0.3219
|
-0.1100
|
Free Cash Flow
1 |
-24.2
|
-8.79
|
-62.59
|
-103.4
|
-185.7
|
-256.2
|
-209.9
|
111.6
|
FCF margin
|
-2,645.62%
|
-1,087.26%
|
-66,532.24%
|
-35,854.05%
|
-31,310%
|
-27,969.62%
|
-1,203.21%
|
70.16%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,406.81%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/8/19
|
8/27/20
|
8/29/21
|
8/29/22
|
8/30/23
|
-
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
0.2731
|
0.5353
|
0.3143
|
-0.1919
|
-
|
-0.0661
|
1.914
|
0.2898
|
3.082
|
0.1486
|
EBITDA
|
-11.51
|
-13.41
|
-18.43
|
-
|
-
|
-
|
-
|
-
|
-141.6
|
-
|
EBIT
1 |
-11.58
|
-13.48
|
-38.51
|
-16.15
|
-56.24
|
-83.02
|
-114
|
-104.3
|
-141.7
|
-163.4
|
Operating Margin
|
-4,239.37%
|
-2,518.97%
|
-12,251.44%
|
8,413.07%
|
-
|
125,676.02%
|
-5,954.51%
|
-35,989.85%
|
-4,597.95%
|
-109,896.59%
|
Earnings before Tax (EBT)
1 |
-11.47
|
-13.6
|
-38.51
|
-16.15
|
-
|
-84.77
|
-116.1
|
-106.7
|
-
|
-150.8
|
Net income
1 |
-7.62
|
-8.909
|
-34.98
|
-10.32
|
-
|
-79.86
|
-113.1
|
-100.7
|
-148.2
|
-152.5
|
Net margin
|
-2,789.99%
|
-1,664.38%
|
-11,130.55%
|
5,375.53%
|
-
|
120,894.81%
|
-5,908.29%
|
-34,760.84%
|
-4,807.68%
|
-102,607.06%
|
EPS
2 |
-
|
-
|
-0.1175
|
-0.0240
|
-0.1487
|
-0.2270
|
-0.2422
|
-0.2416
|
-0.2500
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
8/27/20
|
2/21/21
|
8/29/21
|
2/27/22
|
8/29/22
|
2/22/23
|
8/30/23
|
2/28/24
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
154
|
212
|
-
|
Net Cash position
1 |
21.5
|
61.8
|
162
|
64.7
|
137
|
-
|
-
|
97.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.6224
x
|
-1.085
x
|
-
|
Free Cash Flow
1 |
-24.2
|
-8.79
|
-62.6
|
-103
|
-186
|
-256
|
-210
|
112
|
ROE (net income / shareholders' equity)
|
-60.4%
|
-34.5%
|
-50.4%
|
-101%
|
-677%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-49.9%
|
-34.5%
|
-
|
-93.5%
|
-180%
|
-
|
-
|
-
|
Assets
1 |
41.87
|
47.96
|
-
|
143.8
|
122.2
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.2000
|
0.3800
|
0.5300
|
-
|
-0.0200
|
-0.2400
|
-0.2500
|
0.1200
|
Cash Flow per Share
2 |
-0.1700
|
-0.0500
|
-0.2000
|
-
|
-0.4200
|
-0.3800
|
-0.2500
|
0.3100
|
Capex
1 |
0.02
|
0.01
|
0.02
|
-
|
0.03
|
0.02
|
0.02
|
0.01
|
Capex / Sales
|
1.98%
|
0.9%
|
18.51%
|
-
|
5.7%
|
2.46%
|
0.09%
|
0.01%
|
Announcement Date
|
8/8/19
|
8/27/20
|
8/29/21
|
8/29/22
|
8/30/23
|
-
|
-
|
-
|
Last Close Price
0.65
AUD Average target price
0.8974
AUD Spread / Average Target +38.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +14.91% | 285M | | +22.81% | 46.81B | | +46.56% | 41.29B | | -1.88% | 41.37B | | -6.20% | 28.87B | | +11.33% | 26.06B | | -21.00% | 19.13B | | -1.43% | 11.96B | | +30.73% | 12.39B | | -0.48% | 12.08B |
Other Biotechnology & Medical Research
|